Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Illumina, Inc.
Illumina, Inc. News
Illumina, Inc. Quantitative Score
About Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Illumina, Inc. Earnings & Revenue
Illumina, Inc. Financials
Table Compare
Compare ILMN metrics with: | |||
|---|---|---|---|
Earnings & Growth | ILMN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ILMN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ILMN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ILMN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Illumina, Inc. Income
Illumina, Inc. Balance Sheet
Illumina, Inc. Cash Flow
Illumina, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Illumina, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Illumina, Inc. Executives
| Name | Role |
|---|---|
| Mr. Charles E. Dadswell Esq. | Senior Vice President & General Counsel |
| Mr. Jacob Thaysen Ph.D. | Chief Executive Officer & Director |
| Ms. Carissa L. Rollins | Chief Information Officer |
| Ms. Sallilyn Schwartz | Vice President of Investor Relations |
| Mr. Jakob Wedel | Chief Strategy & Corporate Development Officer and Chief Executive Officer Chief of Staff |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Charles E. Dadswell Esq. | Senior Vice President & General Counsel | Male | 1959 | 1.03M |
| Mr. Jacob Thaysen Ph.D. | Chief Executive Officer & Director | Male | 1975 | 796.63K |
| Ms. Carissa L. Rollins | Chief Information Officer | Female | 1970 | 693.52K |
| Ms. Sallilyn Schwartz | Vice President of Investor Relations | Female | -- | |
| Mr. Jakob Wedel | Chief Strategy & Corporate Development Officer and Chief Executive Officer Chief of Staff | Male | -- |
Illumina, Inc. Insider Trades
| Date | 15 Aug |
| Name | Dadswell Charles |
| Role | SVP, General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 989 |
| Date | 5 Jul |
| Name | Cunningham Everett |
| Role | SVP, Chief Commercial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 36860 |
| Date | 5 Jul |
| Name | Cunningham Everett |
| Role | SVP, Chief Commercial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18430 |
| Date | 28 Jun |
| Name | Ullem Scott B. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 205 |
| Date | 10 Jun |
| Name | Cunningham Everett |
| Role | SVP, Chief Commercial Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Aug | Dadswell Charles | SVP, General Counsel | Disposed | D-Return | 989 |
| 5 Jul | Cunningham Everett | SVP, Chief Commercial Officer | Acquired | A-Award | 36860 |
| 5 Jul | Cunningham Everett | SVP, Chief Commercial Officer | Acquired | A-Award | 18430 |
| 28 Jun | Ullem Scott B. | Director | Acquired | A-Award | 205 |
| 10 Jun | Cunningham Everett | SVP, Chief Commercial Officer | Disposed | 0 |